Skip to content

Nosology and attribution

TL;DR — Hypertensive heart disease (HHD) has no single universally accepted case definition. In clinical research it usually means cardiac structural or functional injury plausibly caused by sustained hypertension; in administrative and mortality systems it is a coded causal attribution; in Global Burden of Disease (GBD) work it is a modeled cause category. These constructs overlap but are not interchangeable (Nemtsova 2023, PMID 37048689; Yang 2023, PMID 37698022). A defensible HHD dataset therefore needs four separate fields—blood-pressure exposure, cardiac phenotype, competing causes, and attribution method—rather than one binary label. The unresolved controversy is whether HHD is a coherent disease entity or an umbrella over several pressure-associated phenotypes (Nwabuo 2020, PMID 32016791; Bellicini 2025, PMID 40760163).

1. Why the name is unstable

The narrow historical formulation treated left-ventricular hypertrophy (LVH) and diastolic dysfunction as the early manifestations of cardiac target-organ injury from hypertension (Diamond 2005, PMID 16097361). Broader formulations include atrial remodeling, fibrosis, microvascular dysfunction, coronary disease without obstructive epicardial disease, atrial and ventricular arrhythmia, and heart failure with preserved or reduced ejection fraction (Prisant 2005, PMID 15860963; Nwabuo 2020, PMID 32016791).

That expansion creates a boundary problem: hypertension is common, most listed phenotypes have multiple causes, and a temporal association is not sufficient attribution. A 2023 review found no comprehensive, generally accepted universal definition or classification incorporating all structural, functional, vascular and rhythm manifestations (Nemtsova 2023, PMID 37048689).

Use of “HHD” What is observed What is inferred Main failure mode
Bedside diagnosis Hypertension plus cardiac findings Hypertension substantially caused the findings Competing causes incompletely excluded
Imaging cohort LV mass, geometry, strain, diastolic indices or fibrosis The measured phenotype represents hypertensive remodeling Referral and threshold dependence
Clinical trial Eligibility phenotype plus pressure criteria A treatment effect applies to HHD Surrogate endpoint substituted for clinical benefit
Hospital discharge coding Diagnoses documented and coded A causal hypertension–heart link Coding practice and reimbursement effects
Death certificate Underlying and contributing causes HHD initiated the fatal sequence Single-cause compression of multimorbidity
GBD model Multiple input streams and statistical models Population burden belongs to the HHD cause category Modeled construct read as measured prevalence

The imaging perspective is especially useful for phenotype definition but does not solve attribution: echo and CMR can characterize hypertrophy, fibrosis and function, yet none directly measures the fraction caused by hypertension (Ismail 2023, PMID 37176563; Huang 2024, PMID 39076964).

2. Phenotype is not etiology

Cardiac finding Compatible with HHD Important competing explanations Minimum attribution work
Increased LV mass Yes Obesity, athletic remodeling, aortic stenosis, HCM, amyloidosis, CKD BP history, loading conditions, family history, valve assessment, phenotype-specific testing
Concentric remodeling Yes Aging, aortic stenosis, infiltrative disease Relative wall thickness plus LV mass and clinical context
Diffuse interstitial fibrosis Yes Diabetes, CKD, inflammatory and infiltrative cardiomyopathy CMR pattern, renal/metabolic context, ischemic assessment where indicated
Diastolic dysfunction Yes Aging, obesity, AF, ischemia, diabetes, valvular disease Multivariable echo interpretation rather than one index
Left-atrial enlargement Yes AF, mitral disease, obesity, volume overload Rhythm and valve history, volume status
HFpEF Common hypertension-associated endpoint Obesity, CKD, AF, amyloidosis, pulmonary disease Syndrome confirmation plus phenotype assessment
HFrEF Possible late phenotype Ischemic, genetic, toxic, inflammatory and valvular cardiomyopathy Standard cardiomyopathy evaluation

Hypertension is therefore neither necessary for every phenotype in the table nor sufficient to assign it to HHD. The most reproducible approach is to record phenotype and attribution separately (Nwabuo 2020, PMID 32016791; Nadruz 2015, PMID 24804791).

3. The disputed “hypertension → LVH → failure” sequence

The traditional sequence describes pressure overload, concentric hypertrophy, diastolic dysfunction, chamber dilation and systolic failure. Contemporary reviews argue that remodeling is more heterogeneous: concentric hypertrophy is not the only or necessarily the most frequent geometry, and direct progression from concentric LVH to dilated failure is not universal (Nadruz 2015, PMID 24804791).

A sharper dissent argues that LVH in hypertension rarely progresses directly to HFpEF or HFrEF and that much cardiovascular harm is mediated by atherosclerosis and microvascular dysfunction instead (Bellicini 2025, PMID 40760163). That position conflicts with broader HHD frameworks that incorporate fibrosis, atrial disease and both HF phenotypes (Nwabuo 2020, PMID 32016791; Gallo 2024, PMID 38928371).

The disagreement is partly empirical and partly semantic:

  1. If HHD means any cardiac disease in a person with hypertension, specificity is poor.
  2. If it means LVH caused only by hypertension, sensitivity is poor.
  3. If it means a probabilistic causal contribution of pressure to a multicausal phenotype, a binary code is inadequate.
  4. If it is a population cause category, it may be valid for trend estimation without being a bedside diagnostic rule.

4. Administrative coding and cause-of-death attribution

Administrative systems encode hypertensive heart disease and combined heart–kidney disease through linked diagnostic categories. These codes do not supply a standardized imaging phenotype or quantify lifetime pressure exposure. A national analysis of U.S. mortality coded as HHD with heart failure illustrates how such data can measure temporal and demographic disparities, but it remains a death-certificate study rather than a clinical cohort (Goyal 2025, PMID 40083536).

Cause-of-death research shows why single underlying-cause fields are lossy. Linking hospital records to certificates or using multiple causes can redistribute deaths initially assigned to heart failure, materially changing cause-specific estimates (Bierrenbach 2019, PMID 31166417). Brazilian multiple-cause data similarly showed hypertensive disease appearing across causal positions rather than only as the selected underlying cause (Villela 2018, PMID 29870833).

Coding question What a code can answer What it cannot answer alone
Was HHD documented? Yes, within coding completeness Whether criteria were correct
Was hypertension causal? Records the coder/certifier attribution Magnitude or mechanism of causality
Was LVH present? Only if separately coded/documented Imaging definition and measurement quality
Was HF present? Often, as a linked or separate code EF phenotype, congestion evidence or competing etiology
Did HHD cause death? Records selected causal sequence Counterfactual cause or full multimorbidity chain

5. GBD HHD is a modeled cause category

GBD estimates synthesize vital registration, verbal autopsy, surveillance and other sources through cause-of-death and disease models. The 2021 cause analysis used 56,604 data sources across 204 countries and territories; outputs are model-based estimates with uncertainty intervals, not a pooled imaging survey (GBD 2021 Causes of Death Collaborators 2024, PMID 38582094).

The GBD 2023 cardiovascular analysis similarly quantified 18 cardiovascular subcauses and risk attribution across 204 countries and territories (Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators 2025, PMID 40990886). Its cause-of-death companion estimated 292 causes by age, sex, place and year through 2023 (GBD 2023 Causes of Death Collaborators 2025, PMID 41092928).

HHD-specific secondary analyses have reported older-adult trends across 204 countries, U.S. prevalence and mortality trends, sex-stratified patterns, national Polish estimates, and projections (Yang 2023, PMID 37698022; Abughazaleh 2024, PMID 38718934; Khalid 2025, PMID 40565965; Miazgowski 2021, PMID 34336015; Li 2025, PMID 41350658). These papers share a modeled ontology; agreement among them does not validate a clinical case definition.

Observed sex differences require cautious interpretation because biology, hypertension exposure, health-system contact, coding, competing mortality and the modeling pipeline can all contribute (Chan 2024, PMID 37607268). Recent trend analyses extending through 2021 should therefore be compared on age standardization, cause definition and input version, not only their headline direction (Liu 2025, PMID 40604684).

6. Denominators that must never be merged

Denominator Appropriate numerator Appropriate claim
All adults in a measured survey Imaging-defined remodeling Prevalence of that specified phenotype
Adults with diagnosed hypertension LVH/diastolic dysfunction by protocol Target-organ-damage prevalence among treated/untreated hypertension
Echocardiography referrals Abnormal echo phenotype Referral-cohort distribution, not population prevalence
Hospital discharges HHD diagnostic codes Coded hospitalization burden
Registered deaths Underlying or multiple-cause HHD codes Mortality attribution pattern
GBD population-year Modeled HHD cases/deaths/DALYs Modeled population burden

The global prevalence of hypertension itself—measured from 1,201 population-representative studies with 104 million participants—is an exposure denominator, not the prevalence of HHD (NCD-RisC 2021, PMID 34450083).

7. A minimum research definition

A study using “HHD” should publish the following fields:

Domain Minimum field Preferred detail
Pressure exposure Hypertension definition Device, setting, repeated measures, ABPM/home data, duration and treatment
Cardiac phenotype Prespecified criterion Modality, formula, indexation, sex-specific threshold, laboratory
Function Systolic and diastolic measures EF, GLS, E/e′, atrial measures, rhythm at acquisition
Tissue Fibrosis assessment if claimed LGE pattern, native T1, ECV, scanner/vendor/reference values
Competing causes Exclusion protocol Valve, ischemic, genetic, infiltrative, renal and metabolic assessment
Attribution Explicit rule Definite/probable/possible rather than silent assumption
Outcome Prespecified endpoint Clinical events separated from imaging surrogates

Diffuse interstitial fibrosis deserves its own field because it may contribute to mechanical, electrical and perfusion abnormalities, but its detection and causal specificity remain imperfect (González 2024, PMID 38084597).

8. Proposed attribution grades

The following is a knowledge-base synthesis, not a validated clinical score:

Grade Evidence pattern Suitable wording
A — strong Documented sustained pressure exposure; compatible phenotype; major alternatives actively excluded “HHD phenotype strongly attributable to hypertension”
B — probable Hypertension and compatible phenotype; incomplete exclusion or exposure history “Probable HHD”
C — possible Hypertension plus nonspecific cardiac abnormality “Cardiac disease with hypertension; attribution uncertain”
D — coded/modelled Administrative, certificate or GBD category without clinical phenotyping “Coded/modelled HHD,” never “imaging-confirmed HHD”

This separation would allow clinical cohorts and population models to coexist without pretending they measure the same construct. It also exposes the central research target: validation against prognosis and treatment response rather than consensus alone (Wang 2025, PMID 39997480; Huang 2024, PMID 39076964).

Open questions

  • Can an attribution rule combining longitudinal pressure load, multimodal phenotype and exclusion of competing causes improve reproducibility beyond either diagnostic codes or LVH alone? (Nemtsova 2023, PMID 37048689; Ismail 2023, PMID 37176563)
  • What fraction of GBD-coded HHD deaths would meet a prespecified clinical phenotype if linked to lifetime records and imaging? (Yang 2023, PMID 37698022; Bierrenbach 2019, PMID 31166417)
  • Is HHD best modeled as one disease, several endophenotypes, or a causal contribution across conventional cardiomyopathy and HF labels? (Nwabuo 2020, PMID 32016791; Bellicini 2025, PMID 40760163)
  • Which attribution uncertainty should be propagated into sex, region and time-trend comparisons? (Chan 2024, PMID 37607268; Khalid 2025, PMID 40565965)

References

  1. Nwabuo CC, et al. Pathophysiology of Hypertensive Heart Disease: Beyond Left Ventricular Hypertrophy. Curr Hypertens Rep. 2020;22:11. PMID 32016791
  2. Nemtsova V, et al. Hypertensive Heart Disease: A Narrative Review Series-Part 1: Pathophysiology and Microstructural Changes. J Clin Med. 2023;12. PMID 37048689
  3. Bellicini MG. Hypertensive heart disease: is it really a pathology? Hypertens Res. 2025;48:2737-2739. PMID 40760163
  4. Prisant LM. Hypertensive heart disease. J Clin Hypertens (Greenwich). 2005;7:231-8. PMID 15860963
  5. Diamond JA, et al. Hypertensive heart disease. Hypertens Res. 2005;28:191-202. PMID 16097361
  6. Ismail TF, et al. Hypertensive Heart Disease-The Imaging Perspective. J Clin Med. 2023;12. PMID 37176563
  7. Wang BX. Diagnosis and Management of Hypertensive Heart Disease: Incorporating 2023 European Society of Hypertension and 2024 European Society of Cardiology Guideline Updates. J Cardiovasc Dev Dis. 2025;12. PMID 39997480
  8. Huang X, et al. Hypertensive Heart Disease: Mechanisms, Diagnosis and Treatment. Rev Cardiovasc Med. 2024;25:93. PMID 39076964
  9. Yang R, et al. Global, regional, and national burden of hypertensive heart disease among older adults in 204 countries and territories between 1990 and 2019: a trend analysis. Chin Med J (Engl). 2023;136:2421-2430. PMID 37698022
  10. Abughazaleh S, et al. Trends of hypertensive heart disease prevalence and mortality in the United States between the period 1990-2019, Global burden of disease database. Curr Probl Cardiol. 2024;49:102621. PMID 38718934
  11. Chan II. Interpreting the observed sex differences in hypertensive heart disease burden. Eur J Prev Cardiol. 2024;31:21-22. PMID 37607268
  12. GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:2100-2132. PMID 38582094
  13. Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators. Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023. J Am Coll Cardiol. 2025;86:2167-2243. PMID 40990886
  14. GBD 2023 Causes of Death Collaborators. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025;406:1811-1872. PMID 41092928
  15. Khalid N, et al. The Global Disease Burden of Hypertensive Heart Disease from 1990 to 2019: A Gender-Stratified Joinpoint Analysis. J Clin Med. 2025;14. PMID 40565965
  16. Liu F, et al. Trends analysis of the global burden of hypertensive heart disease from 1990 to 2021: a population-based study. BMC Public Health. 2025;25:2233. PMID 40604684
  17. Li S, et al. Systematic analysis of global ischemic heart disease and hypertensive heart disease burden, 1990-2021: projections to 2050. BMC Public Health. 2025;26:122. PMID 41350658
  18. Miazgowski T, et al. Epidemiology of hypertensive heart disease in Poland: findings from the Global Burden of Disease Study 2016. Arch Med Sci. 2021;17:874-880. PMID 34336015
  19. Goyal A, et al. Temporal trends and disparities in mortality from hypertensive heart disease with heart failure: A nationwide analysis (1999-2020). Int J Cardiol Cardiovasc Risk Prev. 2025;24:200378. PMID 40083536
  20. Bierrenbach AL, et al. Redistribution of heart failure deaths using two methods: linkage of hospital records with death certificate data and multiple causes of death data. Cad Saude Publica. 2019;35:e00135617. PMID 31166417
  21. Villela PB, et al. Cerebrovascular and hypertensive diseases as multiple causes of death in Brazil from 2004 to 2013. Public Health. 2018;161:36-42. PMID 29870833
  22. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398:957-980. PMID 34450083
  23. Gallo G, et al. Hypertension and Heart Failure: From Pathophysiology to Treatment. Int J Mol Sci. 2024;25. PMID 38928371
  24. González A, et al. Myocardial Interstitial Fibrosis in Hypertensive Heart Disease: From Mechanisms to Clinical Management. Hypertension. 2024;81:218-228. PMID 38084597
  25. Nadruz W. Myocardial remodeling in hypertension. J Hum Hypertens. 2015;29:1-6. PMID 24804791